Skip to main content
Top
Published in: AIDS and Behavior 9/2014

01-09-2014 | Original Paper

Rectal-Specific Microbicide Applicator: Evaluation and Comparison with a Vaginal Applicator Used Rectally

Authors: Alex Carballo-Diéguez, Rebecca Giguere, Curtis Dolezal, José Bauermeister, Cheng-Shiun Leu, Juan Valladares, Lisa C. Rohan, Peter A. Anton, Ross D. Cranston, Irma Febo, Kenneth Mayer, Ian McGowan

Published in: AIDS and Behavior | Issue 9/2014

Login to get access

Abstract

An applicator designed for rectal delivery of microbicides was tested for acceptability by 95 young men who have sex with men, who self-administered 4 mL of placebo gel prior to receptive anal intercourse over 90 days. Subsequently, 24 of the participants self-administered rectally 4 mL of tenofovir or placebo gel over 7 days using a vaginal applicator, and compared both applicators on a Likert scale of 1–10, with 10 the highest rating. Participants reported high likelihood to use either applicator in the future (mean scores 9.3 and 8.8 respectively, p = ns). Those who tested both liked the vaginal applicator significantly more than the rectal applicator (7.8 vs. 5.2, p = 0.003). Improvements in portability, conspicuousness, aesthetics, tip comfort, product assembly and packaging were suggested for both. This rectal-specific applicator was not superior to a vaginal applicator. While likelihood of future use is reportedly high, factors that decrease acceptability may erode product use over time in clinical trials. Further attention is needed to develop user-friendly, quick-acting rectal microbicide delivery systems.

Resumen

Un aplicador diseñado para administrar los microbicidas rectales fue probado para determinar su aceptabilidad por 95 hombres jóvenes que tienen sexo con hombres, quienes auto-administraron 4 mL de un gel placebo antes del sexo anal receptivo durante 90 días. Posteriormente, 24 de los participantes auto-administraron rectalmente 4 mL de un gel tenofovir o placebo durante 7 días usando un aplicador vaginal, y compararon ambos aplicadores en una escala Likert de 1 a 10, 10 siendo la calificación más alta. Los participantes reportaron alta probabilidad de usar cualquiera de los dos aplicadores en el futuro (calificación media 9.3 y 8.8, respectivamente, p = ns). A los que probaron ambos les gustó significativamente más el aplicador vaginal que el rectal (7.8 vs. 5.2, p = 0.003). Se dieron sugerencias para mejorar la portabilidad, visibilidad, estética, comodidad de la punta, ensamblaje y embalaje de ambos aplicadores. Este aplicador específicamente para uso rectal no fue superior al aplicador vaginal. Aunque se reportó una alta probabilidad de uso en el futuro, los factores que disminuyen la aceptabilidad podrían afectar el uso del producto con el tiempo en los ensayos clínicos. Se necesita enfocar más atención en el desarrollo de sistemas de administración de microbicidas rectales que sean fáciles de usar y rápidas.
Literature
1.
go back to reference Carballo-Diéguez A, Stein Z, Sáez H, Dolezal C, Nieves-Rosa L, Díaz F. Frequent use of lubricants for anal sex among men who have sex with men: the HIV prevention potential of a microbicidal gel. Am J Public Health. 2000;90(7):1117–21.PubMedCentralPubMedCrossRef Carballo-Diéguez A, Stein Z, Sáez H, Dolezal C, Nieves-Rosa L, Díaz F. Frequent use of lubricants for anal sex among men who have sex with men: the HIV prevention potential of a microbicidal gel. Am J Public Health. 2000;90(7):1117–21.PubMedCentralPubMedCrossRef
2.
go back to reference Gorbach PM, Weiss RE, Fuchs E, Jeffries RA, Hezerah M, Brown S, et al. The slippery slope: lubricant use and rectal sexually transmitted infections: a newly identified risk. Sex Transm Dis. 2012;39(1):59–64.PubMedCentralPubMedCrossRef Gorbach PM, Weiss RE, Fuchs E, Jeffries RA, Hezerah M, Brown S, et al. The slippery slope: lubricant use and rectal sexually transmitted infections: a newly identified risk. Sex Transm Dis. 2012;39(1):59–64.PubMedCentralPubMedCrossRef
3.
go back to reference Javanbakht M, Murphy R, Gorbach P, LeBlanc M-A, Pickett J. Preference and practices relating to lubricant use during anal intercourse: implications for rectal microbicides. Sex Health. 2010;7(2):193–8.PubMedCrossRef Javanbakht M, Murphy R, Gorbach P, LeBlanc M-A, Pickett J. Preference and practices relating to lubricant use during anal intercourse: implications for rectal microbicides. Sex Health. 2010;7(2):193–8.PubMedCrossRef
4.
go back to reference Gross M, Celum CL, Tabet SR, Kelly CW, Coletti AS, Chesney MA. Acceptability of a bioadhesive nonoxynol-9 gel delivered by an applicator as a rectal microbicide. Sex Transm Dis. 1999;26(10):572–8.PubMedCrossRef Gross M, Celum CL, Tabet SR, Kelly CW, Coletti AS, Chesney MA. Acceptability of a bioadhesive nonoxynol-9 gel delivered by an applicator as a rectal microbicide. Sex Transm Dis. 1999;26(10):572–8.PubMedCrossRef
5.
go back to reference Anton PA, Saunders T, Elliott J, Khanukhova E, Dennis R, Adler A, et al. First phase 1 double-blind, placebo-controlled, randomized rectal microbicide trial using UC781 gel with a novel index of ex vivo efficacy. PLoS One. 2011;6(9):e23243.PubMedCentralPubMedCrossRef Anton PA, Saunders T, Elliott J, Khanukhova E, Dennis R, Adler A, et al. First phase 1 double-blind, placebo-controlled, randomized rectal microbicide trial using UC781 gel with a novel index of ex vivo efficacy. PLoS One. 2011;6(9):e23243.PubMedCentralPubMedCrossRef
6.
go back to reference Ventuneac A, Carballo-Diéguez A, McGowan I, Dennis R, Adler A, Khanukhova E, et al. Acceptability of UC781 gel as a rectal microbicide among HIV-uninfected women and men. AIDS Behav. 2010;14(3):618–28.PubMedCentralPubMedCrossRef Ventuneac A, Carballo-Diéguez A, McGowan I, Dennis R, Adler A, Khanukhova E, et al. Acceptability of UC781 gel as a rectal microbicide among HIV-uninfected women and men. AIDS Behav. 2010;14(3):618–28.PubMedCentralPubMedCrossRef
7.
go back to reference Pines HA, Gorbach PM, Weiss RE, Hess K, Murphy R, Saunders T, et al. Acceptability of potential rectal microbicide delivery systems for HIV prevention: a randomized crossover trial. AIDS Behav. 2013;17(3):1002–15.PubMedCentralPubMedCrossRef Pines HA, Gorbach PM, Weiss RE, Hess K, Murphy R, Saunders T, et al. Acceptability of potential rectal microbicide delivery systems for HIV prevention: a randomized crossover trial. AIDS Behav. 2013;17(3):1002–15.PubMedCentralPubMedCrossRef
8.
go back to reference Mabragaña M, Carballo-Diéguez A, Giguere R. Young women’s experience with using videoconferencing for the assessment of sexual behavior and microbicide use. Telemed J E. 2013;19(11):866–71. Mabragaña M, Carballo-Diéguez A, Giguere R. Young women’s experience with using videoconferencing for the assessment of sexual behavior and microbicide use. Telemed J E. 2013;19(11):866–71.
9.
go back to reference MacQueen KM, McLellan E, Kay K, Milstein B. Codebook development for team-based qualitative analysis. Cult Anthropol Methods. 1998;10(2):31–6. MacQueen KM, McLellan E, Kay K, Milstein B. Codebook development for team-based qualitative analysis. Cult Anthropol Methods. 1998;10(2):31–6.
10.
go back to reference NVivo qualitative data analysis software; QSR International Pty Ltd. Version 8. 2008. NVivo qualitative data analysis software; QSR International Pty Ltd. Version 8. 2008.
11.
go back to reference Patton MQ. Qualitative research and evaluation methods. 3rd ed. Thousand Oaks: Sage; 2002. Patton MQ. Qualitative research and evaluation methods. 3rd ed. Thousand Oaks: Sage; 2002.
12.
go back to reference Carballo-Diéguez A, Giguere R, Dolezal C, Bauermeister J, Leu C-S, Valladares J, Frasca T, Labbett R, Cranston RD, Febo I, Mayer K, McGowan I. Adherence to rectal gel use among mainly ethnic minority young men who have sex with men during a 3-month placebo gel trial: implications for microbicide research. AIDS Behav. 2014. doi:10.1007/s10461-014-0768-1 Carballo-Diéguez A, Giguere R, Dolezal C, Bauermeister J, Leu C-S, Valladares J, Frasca T, Labbett R, Cranston RD, Febo I, Mayer K, McGowan I. Adherence to rectal gel use among mainly ethnic minority young men who have sex with men during a 3-month placebo gel trial: implications for microbicide research. AIDS Behav. 2014. doi:10.​1007/​s10461-014-0768-1
13.
go back to reference McGowan I, Hoesley C, Cranston RD, Andrew P, Janocko L, Dai JY, et al. A phase 1 randomized, double blind, placebo controlled rectal safety and acceptability study of tenofovir 1 % gel (MTN-007). PLoS One. 2013;8(4):e60147.PubMedCentralPubMedCrossRef McGowan I, Hoesley C, Cranston RD, Andrew P, Janocko L, Dai JY, et al. A phase 1 randomized, double blind, placebo controlled rectal safety and acceptability study of tenofovir 1 % gel (MTN-007). PLoS One. 2013;8(4):e60147.PubMedCentralPubMedCrossRef
14.
go back to reference Pfister HR, Böhm G. The multiplicity of emotions: a framework of emotional functions in decision making. Judgm Decis Mak. 2008;3(1):5–17. Pfister HR, Böhm G. The multiplicity of emotions: a framework of emotional functions in decision making. Judgm Decis Mak. 2008;3(1):5–17.
15.
go back to reference Carballo-Diéguez A, Dolezal C, Bauermeister JA, O’Brien W, Ventuneac A, Mayer K. Preference for gel over suppository as delivery vehicle for a rectal microbicide: results of a randomised, crossover acceptability trial among men who have sex with men. Sex Transm Infect. 2008;84(6):483–7.PubMedCentralPubMedCrossRef Carballo-Diéguez A, Dolezal C, Bauermeister JA, O’Brien W, Ventuneac A, Mayer K. Preference for gel over suppository as delivery vehicle for a rectal microbicide: results of a randomised, crossover acceptability trial among men who have sex with men. Sex Transm Infect. 2008;84(6):483–7.PubMedCentralPubMedCrossRef
16.
go back to reference Van der Straten A, Stadler J, Montgomery E, Hartmann M, Magazi B, Mathebula F, et al. Women’s experiences with oral and vaginal pre-exposure prophylaxis: the VOICE-C qualitative study in Johannesburg, South Africa. PLoS One. 2014;9(2):e89118.PubMedCentralPubMedCrossRef Van der Straten A, Stadler J, Montgomery E, Hartmann M, Magazi B, Mathebula F, et al. Women’s experiences with oral and vaginal pre-exposure prophylaxis: the VOICE-C qualitative study in Johannesburg, South Africa. PLoS One. 2014;9(2):e89118.PubMedCentralPubMedCrossRef
17.
go back to reference Marrazzo J, Ramjee G, Nair G, Palanee T, Mkhize B, et al. Pre-exposure prophylaxis for HIV in women: daily oral tenofovir, oral tenofovir emtricitabine, or vaginal tenofovir gel in the VOICE Study (MTN 003). Atlanta: Sage; 2013. Marrazzo J, Ramjee G, Nair G, Palanee T, Mkhize B, et al. Pre-exposure prophylaxis for HIV in women: daily oral tenofovir, oral tenofovir emtricitabine, or vaginal tenofovir gel in the VOICE Study (MTN 003). Atlanta: Sage; 2013.
Metadata
Title
Rectal-Specific Microbicide Applicator: Evaluation and Comparison with a Vaginal Applicator Used Rectally
Authors
Alex Carballo-Diéguez
Rebecca Giguere
Curtis Dolezal
José Bauermeister
Cheng-Shiun Leu
Juan Valladares
Lisa C. Rohan
Peter A. Anton
Ross D. Cranston
Irma Febo
Kenneth Mayer
Ian McGowan
Publication date
01-09-2014
Publisher
Springer US
Published in
AIDS and Behavior / Issue 9/2014
Print ISSN: 1090-7165
Electronic ISSN: 1573-3254
DOI
https://doi.org/10.1007/s10461-014-0793-0

Other articles of this Issue 9/2014

AIDS and Behavior 9/2014 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.